Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806355 | 0.91 | TDO2 (0.43) | SLC29A1NPC1ALDH1A1HTTEGFR | |
| SCHEMBL4922340 | 0.87 | MAPT (0.49) | SLC29A1ALDH1A1HTTEGFRPRKCQ | |
| SCHEMBL4916438 | 0.84 | EGFR (0.56) | SLC29A1ALDH1A1HTTEGFRPRKCQ | |
| SCHEMBL2806449 | 0.83 | PRMT1 (0.59) | SLC29A1NPC1HTTPRKCQPRMT1 | |
| SCHEMBL4916234 | 0.82 | SLC29A1 (0.51) | SLC29A1NPC1ALDH1A1HTTEGFR | |
| SCHEMBL4924793 | 0.81 | IDO1 (0.46) | ALDH1A1EGFRTSHRCYP3A4 | |
| SCHEMBL2805416 | 0.81 | PRMT1 (0.42) | NPC1ALDH1A1HTTEGFRPRMT1 | |
| SCHEMBL4920745 | 0.81 | EGFR (0.43) | SLC29A1NPC1ALDH1A1HTTEGFR | |
| SCHEMBL2809181 | 0.80 | NPSR1 (0.48) | ALDH1A1PRMT1 | |
| SCHEMBL4920708 | 0.80 | EGFR (0.42) | SLC29A1NPC1ALDH1A1HTTEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203451-B1 | SUBSTITUTED 6-(ALKYLBENZYLAMINO)PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIV PALACKEHO (CZ) | 2014-07-30 | — | — | EP | disclosed |
| US-20100240537-A1 | Substituted 6-(alkylbenzylamino)purine derivatives for use as cytokinin receptor antagonists and preparations containing these derivatives | FREIE UNIVERSITAT BERLIN (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240537-A1 | Substituted 6-(alkylbenzylamino)purine derivatives for use as cytokinin receptor antagonists and preparations containing these derivatives | ADORA2A, P2RY6, P2RY1 | SLC29A1 26/4885NPC1 2741/4885ALDH1A1 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.